截至6月30日，安图生物股东户数3.42万，较上期增加0.04%；人均流通股16719股，较上期减少0.04%。 2025年1月-6月，安图生物实现营业收入20.60亿元，同比减少6.65%；归母净利润5.71亿元，同比减少 7.83%。 9月22日，安图生物跌0.94%，成交额1.01亿元。两融数据显示，当日安图生物获融资买入额1056.65万 元，融资偿还666.94万元，融资净买入389.71万元。截至9月22日，安图生物融资融券余额合计6.22亿 元。 融资方面，安图生物当日融资买入1056.65万元。当前融资余额6.20亿元，占流通市值的2.72%，融资余 额低于近一年50%分位水平，处于较低位。 融券方面，安图生物9月22日融券偿还100.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量4.55万股，融券余额181.36万元，低于近一年10%分位水平，处于低位。 资料显示，郑州安图生物工程股份有限公司位于河南省郑州经济技术开发区经开第十五大街199号，成 立日期1999年9月15日，上市日期2016年9月1日，公司主营业务涉及体外诊断试剂及仪器的研发、生产 和销售。主营 ...

9月2日，热景生物跌5.15%，截至发稿，报194.10元/股，成交4.20亿元，换手率2.26%，总市值179.95亿 元。热景生物股价已经连续5天下跌，区间累计跌幅16.76%。 从基金十大重仓股角度 数据显示，嘉实基金旗下1只基金重仓热景生物。嘉实中证2000ETF（159535）二季度持有股数409股， 占基金净值比例为0.28%，位居第八大重仓股。根据测算，今日浮亏损失约4306.77元。连续5天下跌期 间浮亏损失1.69万元。 嘉实中证2000ETF（159535）成立日期2023年9月14日，最新规模2057.67万。今年以来收益34.49%，同 类排名1161/4222；近一年收益75.74%，同类排名857/3781；成立以来收益40.56%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 资料显示，北京热景生物技术股份有限公司位于北京市大兴区中关村科技园区大兴生物医药产业基地庆 丰西路55号院7号楼1-5层，成立日期2005年6月23日，上市日期20 ...

Core Viewpoint - The company reported a significant decline in revenue and net profit for the first half of 2025 compared to the same period last year, indicating ongoing financial challenges in its operations. Financial Performance - Revenue for the first half of 2025 was approximately 203.91 million, down from 248.81 million in the same period last year, representing a decrease of about 18% [2] - Total profit for the first half of 2025 was -91.22 million, compared to -43.07 million in the previous year, indicating a worsening loss [2] - Net profit attributable to shareholders was -83.99 million, a decline from -43.47 million year-on-year [2] - The net cash flow from operating activities was 17.37 million, an increase from -3.84 million in the previous year [2] Profitability Metrics - The company's weighted average return on equity for the first half of 2025 was -2.82%, a decrease of 1.5 percentage points year-on-year [28] - The return on invested capital for the first half of 2025 was -3.35%, down 1.59 percentage points from the previous year [28] Cash Flow Analysis - The net cash flow from financing activities was -19.38 million, an increase of 84.08 million compared to the previous year [29] - The net cash flow from investment activities was -85.12 million, worsening from -50.00 million in the same period last year [29] Asset and Liability Changes - As of the end of the first half of 2025, trading financial assets increased by 97.86% compared to the end of the previous year, while other non-current financial assets decreased by 51.34% [41] - Short-term borrowings accounted for 1.54% of total assets, up from 0% at the end of the previous year [44] Shareholder Composition - New shareholders include funds such as Huatai PineBridge Innovation Medical Theme Mixed Securities Investment Fund and ICBC Credit Suisse Frontier Medical Equity Fund, replacing previous shareholders [54] - The largest shareholder, Lin Changqing, holds 23.39% of the total shares, a decrease of 0.059 percentage points [55]

9月1日，安图生物盘中上涨2.02%，截至14:02，报41.39元/股，成交1.30亿元，换手率0.56%，总市值 236.51亿元。 资金流向方面，主力资金净流入331.24万元，特大单买入123.00万元，占比0.94%，卖出0.00元，占比 0.00%；大单买入2652.69万元，占比20.34%，卖出2444.44万元，占比18.75%。 安图生物今年以来股价跌2.34%，近5个交易日跌2.52%，近20日涨2.35%，近60日涨5.75%。 资料显示，郑州安图生物工程股份有限公司位于河南省郑州经济技术开发区经开第十五大街199号，成 立日期1999年9月15日，上市日期2016年9月1日，公司主营业务涉及体外诊断试剂及仪器的研发、生产 和销售。主营业务收入构成为：试剂86.63%，仪器10.99%，其他1.40%，维保收入0.98%。 安图生物所属申万行业为：医药生物-医疗器械-体外诊断。所属概念板块包括：抗原检测、体外诊断、 猴痘概念、医疗器械、中盘等。 截至6月30日，安图生物股东户数3.42万，较上期增加0.04%；人均流通股16719股，较上期减少0.04%。 2025年1月-6月，安图生 ...

Group 1 - The stock price of Antu Bio on August 26 closed at 42.16 yuan, down 0.30 yuan, a decrease of 0.71% from the previous trading day [1] - The trading volume on that day was 31,091 hands, with a transaction amount of 1.31 billion yuan, and a turnover rate of 0.54% [1] - Antu Bio is in the medical device industry, focusing on the research, production, and sales of in vitro diagnostic reagents and instruments, covering areas such as immunodiagnostics, microbiological testing, and molecular diagnostics [1] Group 2 - On August 26, the net outflow of main funds for Antu Bio was 12.4246 million yuan, accounting for 0.05% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow of main funds reached 81.5687 million yuan, representing 0.34% of the circulating market value [1]

Group 1 - The core point of the news is that 热景生物 (Hotgen Biotech) experienced a decline of 5.06% in its stock price, reaching 233.38 yuan per share, with a trading volume of 2.23 billion yuan and a turnover rate of 1.00%, resulting in a total market capitalization of 216.36 billion yuan [1] - Hotgen Biotech, established on June 23, 2005, and listed on September 30, 2019, is primarily engaged in the research, development, production, and sales of in vitro diagnostic reagents and instruments. The revenue composition is as follows: diagnostic reagents 81.20%, diagnostic instruments 15.52%, biological raw materials 2.13%, and others 1.15% [1] Group 2 - From the perspective of fund holdings, 万家基金 (Wanjia Fund) has one fund heavily invested in Hotgen Biotech. The 万家新机遇成长一年持有期混合发起式A (Wanjia New Opportunities Growth One-Year Holding Mixed Fund A) held 115,300 shares in the second quarter, accounting for 2.25% of the fund's net value, ranking as the tenth largest holding. The estimated floating loss today is approximately 1.4356 million yuan [2] - The 万家新机遇成长一年持有期混合发起式A fund was established on December 7, 2021, with a current scale of 579 million yuan. Year-to-date returns are 19.07%, ranking 3976 out of 8194 in its category; the one-year return is 12.44%, ranking 6446 out of 7962; and since inception, it has incurred a loss of 2.49% [2]

Group 1 - The core viewpoint of the news is that Beijing Hotgen Biotech Co., Ltd. experienced a decline in stock price, with a drop of 5.06% to 233.38 CNY per share, and a total market capitalization of 21.636 billion CNY [1] - The company was established on June 23, 2005, and went public on September 30, 2019, focusing on the research, development, production, and sales of in vitro diagnostic reagents and instruments [1] - The main revenue composition of the company includes diagnostic reagents (81.20%), diagnostic instruments (15.52%), biological raw materials (2.13%), and other supplementary products (1.15%) [1] Group 2 - From the perspective of fund holdings, Zhejiang Securities Asset Management has a fund that heavily invests in Hotgen Biotech, specifically the Zhejiang Huijin Quantitative Selected Mixed Fund (006449), which held 36,600 shares, accounting for 4.96% of the fund's net value [2] - The fund has reported a floating loss of approximately 455,700 CNY as of the latest data [2] - The fund was established on March 25, 2019, with a current size of 104 million CNY, and has achieved a year-to-date return of 45.88% [2]

Group 1 - The stock price of Lidman closed at 9.72 yuan on August 19, 2025, down 3.95% from the previous trading day [1] - The opening price for the day was 9.90 yuan, with an intraday high of 10.37 yuan and a low of 9.70 yuan, resulting in a volatility of 6.62% [1] - The total trading volume for the day was 692,433 hands, with a transaction amount of 6.91 billion yuan [1] Group 2 - Lidman's main business includes the research, production, and sales of in vitro diagnostic reagents and instruments, covering areas such as biochemical diagnosis and immunodiagnosis [1] - The company operates in sectors including medical devices, assisted reproduction, and precision medicine [1] Group 3 - On the morning of August 19, Lidman experienced a quick rebound, reaching a price of 10.24 yuan at 9:37 AM, with a rise of over 2% within 5 minutes [1] - The net outflow of main funds for the day was 49.21 million yuan, with a cumulative net outflow of 203 million yuan over the past five trading days [1]

英诺特股价报33.49元，较前一交易日下跌0.21%。盘中最高触及34.24元，最低下探至33.38元，成交额 达1.23亿元。 该公司属于生物制品行业，主营业务为体外诊断试剂及仪器的研发、生产和销售。企业注册地位于北 京，产品涉及流感、痘病毒防治等领域。 风险提示：股市有风险，投资需谨慎。 本文源自：金融界 作者：A股君 数据显示，英诺特当日主力资金净流出642.26万元，近五个交易日累计净流出2879.34万元。 ...

风险提示：股市有风险，投资需谨慎。 8月18日早盘，利德曼出现快速回调走势，9点42分时股价报10.15元，5分钟内跌幅超过2%。当日主力 资金净流出6374.47万元，近五个交易日累计净流出1.35亿元。 截至2025年8月18日15时21分，利德曼最新股价为10.12元，较前一交易日上涨0.20元。当日开盘价为 9.92元，最高触及10.54元，最低下探至9.82元，成交量为775606手，成交金额达7.82亿元。 利德曼主营业务为体外诊断试剂及仪器的研发、生产和销售，产品涵盖生化诊断、免疫诊断等领域。公 司所属行业为医疗器械板块。 ...